You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Breaking news on Genetics & Genomics business, policy & funding.
Prenetics, which operates in 10 countries, will use the funding for R&D and plans to launch a rapid coronavirus nucleic acid test in Q4.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.
The University of Michigan spinout will use the funds to develop its InheRET platform, increase integration with EHRs, as well as increase its workforce and userbase.
The company said it will use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.